ClinicalTrials.gg
RecruitingNCT06827314Updated Feb 14, 2025

Pharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network Model for the Management of Cardiogenic Shock

An observational study in Cardiogenic Shock and Acute Coronary Event, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Shock, Cardiogenic with a site in Italy — 10 open to participants now, 12 under way, none of them phase 3. Shock, Cardiogenic · Italy.

Planned enrollment
7th of 14
500 · median 500
Started
2022
with 1 other
Observational
14 of 20
9 open now
Primary completion
2027-11
later than 8 of 11 live
Registered
20th of 20
by date
Lead sponsor
1 of 20
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Among the 20 studies in Shock, Cardiogenic with a site in Italy, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2022, is one of 14 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 20th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

10 of the 20 studies in Shock, Cardiogenic with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Shock, Cardiogenic with a site in Italy, or all of them as a file.
02

Study summary

The goal of this observational study is to understand and describe the epidemiology of cardiogenic shock in Emilia Romagna with a specific focus on outcome stratified by aetiologies, sex and age. The main outcomes are:

  • Incidence of cardiogenic shock (CS) over the total CICU admissions, CS-related in-hospital mortality and length of hospitalization, stratified by aetiologies, sex and age
  • Epidemiology of patients admitted with CS, regarding age, gender, etiology and modality of presentation (acute or acute on chronic), echocardiographic and haemodynamic data, treatment strategy with inotropes and/or short-term MCS, cardiac arrest.

This is an observational study without intervention. Patients will be treated according to current clinical practice, according to physician judgment and data sheets of each drug used according to clinical practice.

Read the detailed description

This is a multicenter observational study with both a retrospective and a prospective cohort.

Study population will include all consecutive patients diagnosed with cardiogenic shock and admitted to the cardiac intensive care unit of the participating centers.

For the patients enrolled at IRCCS Azienda Ospedaliera-Universitaria di Bologna this study will involve a collaboration with UO Cardiologia.

For the retrospective cohort, patients will be selected based on ICD9 discharge codes and included if they fulfill inclusion criteria after review of hospital charts. The retrospective cohort will serve as a historical comparison regarding epidemiology, treatment strategies and survival.

Incidence and workload burden of CICU will be studied comparing the number of CS patients and the total number of admissions in the study period.

03

Conditions studied

  • Cardiogenic Shock
  • Acute Coronary Event

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

For the prospective cohort, study population consists of all consecutive patients diagnosed with CS and admitted to participating CICUs in the Emilia Romagna region. For the prospective cohort patients will be enrolled after study approval and until 31 December 2027.

Patients will be enrolled upon admission or at the development of CS if already admitted.

Retrospective data will be collected for five years, starting from January 1st 2018 until the starting date of the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old) admitted to a participating CICU with suspected CS of stage from C to E according to SCAI (Society of cardiovascular intervention)classification of cardiogenic shock.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • CS following cardiac surgery (post-cardiotomy), ● Significant polytrauma or neurological injury.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of CS over the total CICU admissions stratified by aetiologies, sex and age.

    Incidence

    Time frame: 5 years

  2. Length of hospitalization, stratified by aetiologies, sex and age.

    Days

    Time frame: 5 years

  3. CS-related in-hospital mortality stratified by aetiologies, sex and age.

    Incidence

    Time frame: 5 years

  4. Epidemiology of patients admitted with CS, regarding age, gender, etiology and modality of presentation (acute or acute on chronic), echocardiographic and haemodynamic data, treatment strategy with inotropes and/or short-term MCS, cardiac arrest.

    Demography description

    Time frame: 5 years

  5. Recovery from cardiogenic shock, defined as improvement to at least SCAI stage B or discharge from CICU to a step-down ward

    Recovery from cardiogenic shock

    Time frame: 5 years

  6. In-hospital survival according to age, etiology, presentation (acute or acute on chronic) and modality of treatment (inotropes or MCS).

    In-hospital survival

    Time frame: 5 years

  7. Rate and reason of unplanned re-hospitalizations within one month after primary discharge

    Rate and reason of unplanned re-hospitalizations

    Time frame: 5 years

  8. Workload burden will be estimated as the percentage of CS admission and the mean duration of CICU stay as compared to other admissions during study period

    Workload burden

    Time frame: 5 years

  9. Rate of adherence to several items and differences between older era (retrospective data) and prospective cohort

    Blood counts, ECG, oxygen saturation and respiratory monitoring.

    Time frame: 5 years

Secondary outcomes

  1. Rate of successful bridge to heart replacement therapy (heart transplant or LVAD implant) in patients potentially eligible (i.e. age < 71 years old) and transferred to IRCCS Policlinico S.Orsola hub center.

    Rate of successful bridge to heart replacement therapy

    Time frame: 5 years

  2. Comparison of survival between patients who underwent HRT as a consequence of CS to elective patients in the study period

    Comparison of survival

    Time frame: 5 years

  3. Description of in-hospital complications such as rate of renal replacement therapy, number of nosocomial infections with therapy and consequent associated mortality.

    Description of in-hospital complications

    Time frame: 5 years

  4. Description of MCS-related complications, including bleeding requiring transfusions, vascular complications including bleeding requiring intervention and limb ischemia.

    Description of MCS-related complications

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2027, 59 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 59 months is above that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Feb 14, 2025
StartActual
Dec 6, 2022
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06827314
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Dec 6, 2022
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 14, 2025

Study contacts

Luciano Potena, MD
Contact
scompenso.trapiantocuore@aosp.bo.it
0512143725
Luciano G Potena, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion